Search Results

You are looking at 51 - 60 of 135 items for :

Clear All
Full access

Gianfranco Puppo, Gian Paolo Mattioli, Sara De Magistris, Erilda Kamberi, Maria Serafini, Giordano Riccioni, Yuri Rosati and Francesca Marchesani

with advanced NSCLC in a real-life context, the efficacy of the treatment was independent of the age. Factors associated with lower survival were the presence of brain or liver metastases or previous treatment with a tyrosine kinase inhibitor (TKI) drug.

Full access

Patrick A. Brown, Bijal Shah, Amir Fathi, Matthew Wieduwilt, Anjali Advani, Patricia Aoun, Stefan K. Barta, Michael W. Boyer, Teresa Bryan, Patrick W. Burke, Ryan Cassaday, Peter F. Coccia, Steven E. Coutre, Lloyd E. Damon, Daniel J. DeAngelo, Olga Frankfurt, John P. Greer, Hagop M. Kantarjian, Rebecca B. Klisovic, Gary Kupfer, Mark Litzow, Arthur Liu, Ryan Mattison, Jae Park, Jeffrey Rubnitz, Ayman Saad, Geoffrey L. Uy, Eunice S. Wang, Kristina M. Gregory and Ndiya Ogba

novel tyrosine kinase inhibitors (TKIs; for Philadelphia chromosome [Ph]–positive ALL), targeted agents, and immunotherapies, fundamentally changing the treatment landscape for those with relapsed/refractory (R/R) ALL. 21 , 22 The NCCN Clinical

Full access

Gregory L. Riely

explained. Despite initial response rates, patients will eventually develop resistance to EGFR tyrosine kinase inhibitors (TKIs). More than 60% of EGFR -mutant patients will have a new T790M mutation at the time of resistance. This mutation cannot be

Full access

Enrique Soto-Perez-de-Celis, Pedro N. Aguiar Jr, Mónica L. Cordón, Yanin Chavarri-Guerra and Gilberto de Lima Lopes Jr

multikinase tyrosine kinase inhibitors (TKIs) for patients with HCC and conserved liver function. Two TKIs, sorafenib and regorafenib, have shown improvements in survival compared with placebo and have subsequently been approved by the FDA for use as first

Full access

Leora Horn

(24% vs 1%). Since the IPASS trial, 6 different trials have been performed asking essentially the same question, noted Dr. Horn: Is there a difference between tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, or afatinib and platinum

Full access

Giuseppe Saglio and Carmen Fava

substantial number of good cytogenetic responses in patients with CML, 3 and it has been substantially validated in patients treated with imatinib and other tyrosine kinase inhibitors (TKIs). 4 - 6 However, in the presence of a similar degree of leukemic

Full access

David S. Ettinger, Douglas E. Wood, Wallace Akerley, Lyudmila A. Bazhenova, Hossein Borghaei, David Ross Camidge, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, Todd L. Demmy, Thomas J. Dilling, M. Chris Dobelbower, Ramaswamy Govindan, Frederic W. Grannis Jr, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Lee M. Krug, Rudy P. Lackner, Michael Lanuti, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Steven E. Schild, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory and Miranda Hughes

EGFR mutations in their tumors. 4 – 6 , 8 – 12 Patients whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations are usually highly sensitive to EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. 6 , 11 , 12 Patients whose tumors have

Full access

Susan O'Brien, Camille N. Abboud, Mojtaba Akhtari, Jessica Altman, Ellin Berman, Daniel J. DeAngelo, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Joseph O. Moore, Javier Pinilla-Ibarz, Jerald P. Radich, Vishnu V.B. Reddy, Neil P. Shah, Paul J. Shami, B. Douglas Smith, David S. Snyder, Meir Wetzler and Furhan Yunus

(TKI) therapy for the mother or its potential risk to the fetus must be carefully evaluated on an individual basis before either agent is administered to a pregnant woman. Men desiring conception should consider sperm cryopreservation before initiation

Full access

Philip E. Lammers, Christine M. Lovly and Leora Horn

surprised to find the T790M mutation in this treatment-naïve patient, because the T790M mutation has been shown to be one mechanism through which lung cancers develop resistance to EGFR tyrosine kinase inhibitor (TKI) therapy. 1 , 2 The oncologist

Full access

Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ephraim S. Casper, Ernest U. Conrad III, Thomas F. DeLaney, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane III, Joel Mayerson, Sean V. McGarry, Christian Meyer, Richard J. O’Donnell, Alberto S. Pappo, I. Benjamin Paz, John D. Pfeifer, Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Brian A. Van Tine, Jeffrey D. Wayne, Mary Anne Bergman and Hema Sundar

sunitinib are limited because of the small number of patients who are surgical candidates after failure of 2 tyrosine kinase inhibitor (TKI) therapies. Nevertheless, available evidence (both clinical and preclinical) indicates that although sunitinib is very